125 related articles for article (PubMed ID: 1145668)
1. Aldosterone plasma radioimmunoassay interference by a spirolactone metabolite.
Sadée W; Finn AM; Schmiedek P; Baethmann A
Steroids; 1975 Mar; 25(3):301-11. PubMed ID: 1145668
[TBL] [Abstract][Full Text] [Related]
2. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
Datta P; Dasgupta A
Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
[TBL] [Abstract][Full Text] [Related]
3. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
[TBL] [Abstract][Full Text] [Related]
4. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
Dasgupta A; Johnson MJ
J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
[TBL] [Abstract][Full Text] [Related]
5. The effects of canrenoate K on corticosteroid biosynthesis in nephrectomized dogs.
Lasaridis AN; Tourkantonis A; Spanos P; Apostolopoulou K; Pharmakiotis A
J Steroid Biochem; 1984 Apr; 20(4A):923-9. PubMed ID: 6323885
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone and potassium canrenoate in normal man.
Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
[TBL] [Abstract][Full Text] [Related]
7. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
Foukaridis GN
Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
[TBL] [Abstract][Full Text] [Related]
8. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
Dasgupta A; Johnson MJ; Sengupta TK
J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of canrenoate-K and prorenoate-K upon aldosterone biosynthesis in perifused frog interrenal glands.
Delarue C; Leboulenger F; Tonon MC; Jegou S; Leroux P; Kusmierek MC; Corvol P; Vaillant R; Vaudry H
Steroids; 1979 Sep; 34(3):319-32. PubMed ID: 494369
[TBL] [Abstract][Full Text] [Related]
10. Tissue distribution of 3H-canrenoate potassium in rabbits.
Finn AM; Brown R; Sadée W
J Pharm Sci; 1977 Feb; 66(2):275-7. PubMed ID: 839430
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of spironolactone and potassium canrenoate in humans.
Kojima K; Yamamoto K; Fujioka H; Kaneko H
J Pharmacobiodyn; 1985 Mar; 8(3):161-6. PubMed ID: 4009408
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone and canrenoate-K: relative potency at steady state.
Ramsay L; Asbury M; Shelton J; Harrison I
Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
[TBL] [Abstract][Full Text] [Related]
13. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
Cheng SC; Suzuki K; Sadee W; Harding BW
Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
[TBL] [Abstract][Full Text] [Related]
14. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
Casals-Stenzel J; Schmalbach J; Losert W
Eur J Clin Pharmacol; 1977 Dec; 12(4):247-55. PubMed ID: 590311
[TBL] [Abstract][Full Text] [Related]
15. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
Dasgupta A; Tso G; Wells A
Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
[TBL] [Abstract][Full Text] [Related]
16. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous automated determination of spironolactone metabolites in serum.
Neubert P; Koch K
J Pharm Sci; 1977 Aug; 66(8):1131-4. PubMed ID: 894500
[TBL] [Abstract][Full Text] [Related]
18. A comparison of some extra-renal effects of spironolactone and canrenone.
Huston GJ; Al-Dujaili EA
Br J Clin Pharmacol; 1979 Apr; 7(4):385-92. PubMed ID: 444357
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
van der Merwe PJ; Müller DG; Clark EC
J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
[No Abstract] [Full Text] [Related]
20. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
Dasgupta A; Saffer H; Wells A; Datta P
J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
